Back

Silexion Therapeutics shares surge 60.99% after SIL204 findings

Verifying
  • Silexion Therapeutics reported positive preclinical findings for its lead candidate, SIL204.
  • 60.99%: Shares rose to $0.40 in Monday after-hours trading.
  • Silexion continues site initiation in Israel and regulatory clearances in Germany.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.